J&J Ohio Talc Verdict: Jury Clears Johnson & Johnson in Mesothelioma Wrongful Death Trial

The J&J Ohio talc verdict went to the defense: an Ohio state jury on Friday, October 23, 2026 found in Johnson & Johnson's favor in a wrongful death suit brought by the family of a woman who alleged that her mesothelioma was caused by years of using talc cosmetic products contaminated with asbestos, Law360 reported. The family recovers nothing at trial, and the result gives J&J a fresh defense win in a mesothelioma docket that sits entirely outside its $5.5 billion ovarian cancer settlement and has produced several of the largest single-plaintiff verdicts the company has ever faced.

A single defense verdict does not change the science or the law, and it binds no other jury. But it arrives at a moment when timing matters. The ovarian deal announced on July 27, 2026 is still short of the 95% participation it needs; mesothelioma claims were carved out of it and continue to be tried one by one in state courts; and verdicts in those trials are the main market signal for what an asbestos-in-talc wrongful death claim is worth. This piece sets out what is known about the Ohio case and what is not, places the verdict in J&J's recent mesothelioma trial record, explains the Ohio causation and damages rules that frame any talc trial in the state, walks through the post-trial clock, and closes with what the result means for plaintiffs' firms, defendants and litigation funders.

Who won the Ohio talc mesothelioma trial against Johnson & Johnson?

Johnson & Johnson won. The jury returned a verdict for the company on October 23, 2026, rejecting the family's wrongful death claims. Because the verdict was for the defense, no compensatory or punitive damages were awarded, and the jury never reached any damages question that a plaintiff's verdict would have required.

Law360's report, by Emily Field, describes the forum only as an Ohio state court. In Ohio, civil jury trials of this kind are heard in a county court of common pleas, and several Ohio counties have handled asbestos dockets for decades. The county, the judge, and the case caption had not been widely reported as of October 24, 2026, and they are not stated here because they could not be confirmed from a second source.

What was the Ohio talc case about?

The claim was a Mass Tort staple in its classic form: a wrongful death action by the family of a woman who died of mesothelioma, alleging that her disease was caused by asbestos fibers present in the cosmetic talc she used over a long period. Plaintiffs in these cases typically plead Failure to Warn and Design Defect theories, together with negligence, arguing that the talc mined for J&J's powders contained asbestiform minerals and that the company knew or should have known it. J&J's consistent position, repeated in every talc trial, is that its talc does not contain asbestos and does not cause cancer.

Mesothelioma is a cancer of the lining of the lungs (pleural) or abdomen (peritoneal) that is strongly associated with asbestos exposure. That association is why these cases differ from the ovarian cancer claims consolidated in federal court: the core fight in a mesothelioma trial is rarely whether asbestos can cause the disease, and usually whether the plaintiff's talc actually contained asbestos and whether that exposure, as opposed to some other source, caused the illness.

What is not yet public

Several facts that would explain why this jury came out differently from juries in Baltimore, Minneapolis or Los Angeles had not been reported as of publication:

• the decedent's name, age, diagnosis date, and whether the disease was pleural or peritoneal;
• the length of the trial and the damages the family asked for;
• the questions on the verdict form, and whether the jury rejected exposure, contamination, causation or warning-based liability;
• whether retailers, talc suppliers, or other asbestos defendants were also on trial, and whether any had settled before verdict;
• counsel on each side, and whether the family intends to file post-trial motions.

Each of those details matters to practitioners. A verdict-form answer that the product did not contain asbestos is far more useful to the defense in the next trial than a finding that the plaintiff failed to prove her particular exposure was a substantial factor. Until the verdict form or a post-trial filing surfaces, the safest reading is the narrow one: one Ohio jury, on one evidentiary record, found that the family had not carried its burden.

How does the Ohio verdict compare with other J&J mesothelioma verdicts?

It is a defense win against a backdrop dominated by large plaintiff awards, though not an isolated one. J&J's own securities filings describe the record this way: in talc cases that have gone to trial, the company "has obtained a number of defense verdicts, but there also have been verdicts against the Company." The table below collects the verified mesothelioma trial and appellate results reported since mid-2024. It is not exhaustive; it covers outcomes that could be confirmed from at least two independent reports.

Case / forum	Date	Outcome	Reported detail
Kyung Lee v. Bi-Mart Corp. (Multnomah County, Ore.)	June 3, 2024	Plaintiff verdict, $260 million	$60 million compensatory, $200 million punitive; J&J said it would appeal
Paluzzi (Suffolk County, Mass.)	June 2025	Plaintiff verdict, $8 million	Negligence and breach of warranty
Lovell (Massachusetts)	July 2025	Plaintiff verdict, $42.6 million	Described in coverage as a landmark Massachusetts talc award
Moore (Los Angeles County, Cal.)	October 2025	Plaintiff verdict, $966 million	$16 million compensatory, $950 million punitive
South Carolina state court	October 2025	Defense verdict	Jury found J&J entities not negligent or strictly liable
Craft (Baltimore City, Md.)	December 2025	Plaintiff verdict, more than $1.5 billion	$59.84 million compensatory; $1 billion punitive against J&J; $500 million punitive against Pecos River Talc
Houghton Carley (Ramsey County, Minn.)	December 2025	Plaintiff verdict, $65.5 million	13-day trial; new-trial motion later denied
Lozano (Los Angeles County, Cal.)	June 9, 2026	Plaintiff verdict, $32 million	Jury assigned 100% of liability to J&J
Lee (Pa. Superior Court)	July 7, 2026	2025 defense verdict affirmed	Trial court clarified a verdict slip that initially showed $22 million in punitive damages
Garcia (Ill. App. Ct., 1st Dist.)	July 2026	$45 million verdict affirmed	$33 million survival, $12 million wrongful death; 2026 IL App (1st) 242199
Roy (Orleans Parish, La.)	August 2026	Plaintiff verdict, $10 million	Fault shared with other defendants; J&J's share reported at about $1.2 million
Haddad (Suffolk County, Mass.)	Trial opened October 2026	Pending	Mesothelioma death of a nurse; no verdict reported
Ohio state court	October 23, 2026	Defense verdict	Wrongful death; longtime cosmetic talc use alleged

Three patterns stand out. First, the plaintiff wins are enormous at the top end because of Punitive Damages: the Baltimore, Los Angeles and Oregon verdicts were driven by punitive awards many times the compensatory figure, which is exactly the component most vulnerable on post-trial motion and appeal. Second, the defense wins are real and recurring: South Carolina in 2025, the Pennsylvania verdict the Superior Court affirmed in July 2026, and now Ohio. Third, apportionment can shrink a headline number dramatically, as in New Orleans, where a $10 million verdict translated into roughly $1.2 million against J&J once fault was spread across other defendants including cigarette and cosmetics makers.

For plaintiffs' lawyers valuing inventory, the Ohio verdict is a reminder that the distribution of outcomes includes zeros. For the defense, it is evidence to put in front of mediators that a talc mesothelioma trial is not a guaranteed loss.

Why the mesothelioma trials continue: does the J&J $5.5 billion talc settlement cover mesothelioma?

No. The proposed resolution J&J announced on July 27, 2026 is limited to ovarian cancer claims, roughly 76,000 of them pending in state and federal courts, and it expressly leaves out mesothelioma and future claims. J&J's quarterly report for the period ended September 27, 2026 says the ovarian resolution does not affect the mesothelioma docket, "which remains ongoing." That is why talc mesothelioma trials keep reaching juries in Ohio, Massachusetts, California and elsewhere while the ovarian cases sit frozen in Multidistrict Litigation (MDL) No. 2738 in the District of New Jersey.

The ovarian deal itself remains conditional. Lead plaintiffs' counsel reported earlier in October that 313 firms holding about 66,500 claims, roughly 87.5%, had signed on, short of the 95% threshold J&J requires. If the condition is not met or waived, MDL plaintiffs face a November 19, 2026 response deadline on the court's show-cause order on Specific Causation, covering the 69,340 federal actions pending on October 1, 2026.

The mesothelioma claims have a different history. J&J has said it previously resolved the large majority of filed mesothelioma lawsuits through settlement, and those cases were also outside its last bankruptcy-based proposal through Red River Talc, which a bankruptcy court rejected in 2025. The company retained all talc liabilities when it separated its consumer health business into Kenvue, and its filings say it indemnifies Kenvue for talc costs arising in the United States and Canada. Practically, that means J&J pays whatever a mesothelioma jury awards against Kenvue-branded or legacy entities, as the Baltimore and Illinois cases illustrate. A defense verdict therefore saves J&J directly, and it feeds into the company's negotiating posture with the firms that hold the remaining mesothelioma inventory.

How does Ohio law decide asbestos causation in talc cases?

Ohio is one of the more demanding states for asbestos plaintiffs on causation, by statute. Ohio Revised Code 2307.96 requires a plaintiff to prove both that the injured person was exposed to the particular defendant's asbestos and that this exposure was a substantial factor in causing the injury. The trier of fact must weigh the "manner, proximity, frequency, and length" of the exposure. The Supreme Court of Ohio, in Schwartz v. Honeywell Internatl., Inc., 2018-Ohio-474, held that the "cumulative exposure" theory, under which every exposure above background contributes to the disease, is inconsistent with that statutory test and cannot by itself establish that a given defendant's product was a substantial factor. The court emphasized that the inquiry is individualized for each defendant.

That framework matters in talc cases because the exposure evidence is rarely direct. Plaintiffs typically rely on expert testing of historical product samples, corporate documents about talc mine geology, and expert testimony that consumer use released respirable fibers. Defendants attack each link: whether the tested samples match what the plaintiff actually used, whether the minerals identified are asbestiform or non-asbestiform, and whether another exposure source explains the disease. The Minnesota court that upheld the $65.5 million Houghton Carley verdict rejected J&J's argument that the evidence failed to distinguish asbestiform from non-asbestiform minerals, leaving that question to the jury's assessment of expert credibility. In Ohio, the same factual dispute is filtered through a statute that tells jurors to examine the specific defendant's contribution, not the plaintiff's total asbestos history.

Ohio also screens asbestos claims at the pleading stage. Under R.C. 2307.92(D)(1), an asbestos wrongful death claim cannot proceed without a prima facie showing that includes a diagnosis by a competent medical authority that asbestos exposure was a substantial contributing factor to the death. The Supreme Court of Ohio has continued to police those threshold requirements, most recently in a 2025 lung cancer wrongful death case involving a missing treating-physician report. The Ohio family in the October 23 trial obviously cleared that gate, because the case went to verdict, but the statute shapes how Ohio talc cases are built from the first filing. Daubert Challenge-style fights over the reliability of mineralogy and causation experts also play out in Ohio through Evid.R. 702, as they do in every talc jurisdiction.

Do Ohio damages caps apply to talc wrongful death cases?

Mostly no, for the wrongful death claim itself, but Ohio's caps still shape what a plaintiff's verdict would have been worth. Ohio caps noneconomic damages in tort actions under R.C. 2315.18 at the greater of $250,000 or three times economic loss, up to $350,000 per plaintiff, with no cap for catastrophic physical injuries such as permanent and substantial physical deformity or loss of a limb. But R.C. 2315.18(H)(3) states that the section does not apply to wrongful death actions brought under Chapter 2125. Loss-of-society and mental-anguish damages to survivors in a wrongful death case are therefore generally outside the noneconomic cap. A survival claim for the decedent's own pre-death pain and suffering is a different claim, and practitioners treat it as potentially within the cap framework, so how a family pleads and proves each component changes the exposure.

Punitive damages are capped separately. R.C. 2315.21 limits punitive damages to two times the compensatory damages awarded against that defendant, with a lower limit for individuals and small employers. Measured against the verdicts in the table above, that is a decisive constraint. The $950 million punitive award in Los Angeles was nearly 60 times the $16 million compensatory figure, and the $1 billion punitive award against J&J in Baltimore was roughly 17 times the compensatory damages. A comparable Ohio plaintiff's verdict would have been cut back to a two-to-one ratio by operation of the statute.

There is an irony in the caption of the case that settled those caps. The Supreme Court of Ohio upheld the noneconomic and punitive caps against facial constitutional challenges in Arbino v. Johnson & Johnson, 2007-Ohio-6948, decided December 27, 2007, a case that arose from claims that a J&J unit's birth control patch caused blood clots. The court later carved an as-applied exception in Brandt v. Pompa (2022) for plaintiffs with catastrophic psychological injuries. Bills in the 136th General Assembly, H.B. 447 and S.B. 292, would raise the $250,000 noneconomic figure to $415,000 and index the caps to inflation; neither had been enacted as of their latest reported status.

The damages picture in one place

Ohio rule	What it does	Relevance to a talc wrongful death trial
R.C. 2315.18	Caps noneconomic damages at the greater of $250,000 or 3x economic loss, up to $350,000 per plaintiff	Applies to survival-type claims; catastrophic-injury exception
R.C. 2315.18(H)(3)	Excludes Chapter 2125 wrongful death actions from the cap	Survivors' wrongful death damages generally uncapped
R.C. 2315.21	Caps punitive damages at 2x compensatory per defendant	Would compress any nine-figure punitive award
Arbino v. Johnson & Johnson (2007)	Upheld caps against facial challenge	Caps are settled law, subject to as-applied exceptions
Brandt v. Pompa (2022)	As-applied exception for catastrophic psychological injury	Narrow; non-wrongful-death context

Because the October 23 jury found for J&J, none of these rules came into play in this case. They matter for the next Ohio talc trial, and for anyone pricing Ohio mesothelioma claims against verdicts from Maryland, California or Oregon.

Can the family appeal the Ohio talc verdict?

Yes, on legal error, though a defense verdict is hard to reverse. Under Ohio Civ.R. 59(B), a motion for a new trial must be served within 28 days after entry of judgment, and under App.R. 4(A) a notice of appeal is due within 30 days of the judgment. A timely post-judgment motion such as a new-trial motion tolls the appeal clock until the trial court rules, under App.R. 4(B); an untimely one does not, and a late notice of appeal is a jurisdictional defect. Those deadlines run from the journalized judgment entry, not from the date the jury announced its verdict.

The grounds that typically carry weight in a talc appeal are evidentiary rulings (admission or exclusion of expert testing, corporate documents, or alternative-exposure evidence), jury instructions on causation under R.C. 2307.96, and verdict-form problems. The Pennsylvania appeal J&J won in July 2026 turned on exactly that last category: the Superior Court held that the trial court properly handled jury confusion over a verdict slip that initially showed $22 million in punitive damages, and affirmed judgment for the defense. Appellate courts give juries wide latitude on credibility, so a plaintiff challenging a defense verdict generally must show that a legal ruling, not the weighing of competing experts, drove the result.

What the J&J Ohio talc verdict means for plaintiffs' firms, defendants and funders

For plaintiffs' mesothelioma firms. The verdict is a data point that pushes down the expected value of a tried case, especially in Ohio, where the causation statute, the pleading gate and the punitive cap all cut against the outsized awards seen elsewhere. Firms evaluating venue for new filings will weigh Ohio's rules against jurisdictions such as Maryland, California, Minnesota and Illinois, where recent juries and appellate courts have sustained large awards. The details that emerge from the Ohio verdict form will tell firms whether the loss turned on product contamination evidence, which affects every case, or on the decedent's individual exposure history, which affects only cases that look like it. A firm carrying cases on a Contingency Fee basis bears the trial cost of a defense verdict directly, which matters when expert-heavy talc trials can run for weeks.

For Johnson & Johnson and co-defendants. A defense win strengthens the company's position that mesothelioma claims are triable and winnable, which is the leverage it needs in negotiating with the firms holding the remaining mesothelioma inventory outside the ovarian deal. It also supports J&J's appellate narrative that the large plaintiff verdicts are outliers. Co-defendants in talc trials, including retailers and other cosmetics makers, will look to the Ohio record for apportionment arguments, given how the New Orleans jury spread fault across several companies.

For ovarian claimants and the 95% threshold. The Ohio case is a mesothelioma case and has no direct legal effect on MDL 2738 or on the ovarian settlement. Indirectly, every defense verdict in a talc trial reinforces the message J&J has pressed on holdout ovarian firms: that trial is uncertain, and that the specific-causation show-cause order is a real risk if the deal fails. Firms deciding whether to sign on before the participation count is finalized will read the result as one more reason the settlement grid may compare well with litigation.

For litigation funders. Outcomes in talc mesothelioma trials vary as widely as the table above shows, from zero to more than $1.5 billion, which is the core underwriting problem for Third-Party Litigation Funding tied to these cases. A defense verdict in a state with statutory damages caps argues for jurisdiction-specific pricing rather than a single national value per claim, and for weighting portfolio exposure by venue. Funders backing mesothelioma inventories will want the verdict form before revising their models.

For defense counsel in other asbestos litigation. Ohio's R.C. 2307.96 and Schwartz v. Honeywell apply to every asbestos product, not only talc. A talc defense win built on individualized exposure proof is a template defense lawyers in brake, gasket and building-products cases will study as closely as talc specialists.

What to watch next

• The verdict form and judgment entry. The jury's specific findings will determine how useful the result is in other trials and in negotiations.
• Post-trial motions. Any Civ.R. 59 motion must be served within 28 days of the judgment entry; that filing would preview the family's appellate issues.
• The Haddad trial in Boston. The mesothelioma trial that opened in Suffolk County Superior Court in October 2026 is the next scheduled data point; Massachusetts juries returned $8 million and $42.6 million verdicts against J&J in 2025.
• The ovarian participation count. Biweekly reports to the MDL 2738 court will show whether the deal reaches 95% or whether J&J waives the condition, ahead of the November 19, 2026 show-cause response date.
• Appeals of the nine-figure verdicts. Post-trial and appellate rulings in the Baltimore and Los Angeles cases will show how much of the headline punitive damages survive, which in turn affects how much a defense verdict like Ohio's shifts overall settlement values.

FAQ

Who won the Ohio talc mesothelioma trial against Johnson & Johnson?

Johnson & Johnson. An Ohio state jury returned a defense verdict on October 23, 2026 in a wrongful death suit claiming that asbestos in talc cosmetic products caused a woman's mesothelioma, so the family recovered no damages.

Does the J&J $5.5 billion talc settlement cover mesothelioma?

No. The July 27, 2026 proposal covers only about 76,000 ovarian cancer claims and excludes mesothelioma and future claims; J&J's latest quarterly report says the mesothelioma docket remains ongoing, which is why cases like the Ohio one still go to trial.

How does the Ohio verdict compare with other J&J mesothelioma verdicts?

It is one of a handful of recent defense wins, alongside South Carolina in October 2025 and a Pennsylvania verdict affirmed in July 2026, set against large plaintiff verdicts such as more than $1.5 billion in Baltimore, $966 million in Los Angeles, $65.5 million in Minnesota and $32 million in Los Angeles in June 2026.

Can the family appeal the Ohio talc verdict?

Yes. Ohio Civ.R. 59(B) gives 28 days from the judgment entry to serve a new-trial motion, and App.R. 4(A) gives 30 days to file a notice of appeal, with a timely post-judgment motion tolling that deadline; reversal generally requires a legal error, not a disagreement with how the jury weighed the experts.

Do Ohio damages caps apply to talc wrongful death cases?

The noneconomic cap in R.C. 2315.18 does not apply to wrongful death actions under Chapter 2125, but punitive damages are limited to twice compensatory damages under R.C. 2315.21, and survival claims may fall within the noneconomic cap. Because the October 23 verdict was for the defense, no cap was applied in this case.

What does the Ohio verdict mean for pending talc mesothelioma lawsuits?

It does not bind any other court, but it lowers the expected value of trying an Ohio talc case, gives J&J leverage in mesothelioma settlement talks, and adds to the uncertainty that ovarian claimants weigh in deciding whether to join the $5.5 billion deal.